Yan Leyfman, Co-founder and executive director of MedNews Week, posted on LinkedIn:
“Pluri (Nasdaq: PLUR) announces a newly granted U.S. patent for its proprietary immune cell expansion technology, including MAIT cells — a unique subset of T cells with strong potential in solid tumor immunotherapy.
With over 250 patents now pending, allowed, or granted, this milestone strengthens Pluri’s leadership in scalable, placental-derived immune cell platforms.
Why it matters:
- MAIT cells have been difficult to expand outside the body — Pluri’s technology changes that.
- Proprietary 3D bioreactors mimic the natural immune environment.
- Enables “off-the-shelf” cell therapies.
- Low alloreactivity reduces the risk of GVHD and may enhance durability.”